TB-500 + BPC-157 Tendon Repair Research Protocol

The most compelling published basis for a tendon-specific BPC-157 + TB-500 research protocol comes from the Zagreb laboratory of Professor Predrag Sikiric, whose group has used the Achilles-tendon complete transection model in rats to evaluate pentadecapeptide BPC 157 across multiple publications spanning 2006 to the present. In the canonical Krivic et al. (2006) experiment [PMID:16609969], full tendon transection was performed and BPC-157 was delivered subcutaneously at the repair site — not at a distant site — for a two-week post-operative period. Biomechanical testing at weeks 2 and 4 showed significantly greater load-to-failure and improved collagen-fibre alignment versus untreated controls. The Sikiric group's subsequent collaborations with C.H. Chang and colleagues in the Asia-Pacific region extended this model to characterise the cellular events driving BPC-157's tendon effect, establishing tenocyte migration and tendon outgrowth as the primary outputs [PMID:21030672]. This protocol is the tendon-focused variant of the BPC-157 + TB-500 healing stack, designed around those published tendon-specific findings.

How this differs from the general BPC-157 + TB-500 healing stack

The general healing stack is an 8-week protocol in which BPC-157 is administered as a single twice-daily systemic subcutaneous dose, and TB-500 runs a 4-week full loading phase before tapering. The tendon-repair variant diverges in three specific ways justified by the tendon literature.

First, BPC-157 is split between a local and a systemic injection at each dosing event. The morning dose is administered as close to the target tendon as anatomy permits (peri-tendinous, not intra-tendinous); the evening dose is standard subcutaneous. This mirrors the near-site injection strategy in the Krivic et al. Achilles detachment model, where proximity of BPC-157 delivery to the repair site was a defining feature of the protocol design.

Second, TB-500 loading is compressed to 3 weeks rather than 4. Tendon angiogenesis peaks earlier than in softer, more vascular tissues such as muscle or gastric mucosa. Sustaining a full loading dose into week 4 for a tendon-only objective adds peptide burden without additional published precedent in the tendon-specific literature.

Third, the cycle runs 6 weeks rather than 8. Tendon-specific rodent models document the primary structural endpoints (tensile load, collagen-I:III ratio) at 4 to 6 weeks post-transection. The two additional weeks of the general protocol reflect the broader healing stack's application to myocardial and GI targets, which have different repair kinetics.

Mechanism of action — each peptide

Summarised studies on tendon repair

The tendon-specific evidence base for this stack draws principally from the Sikiric group's Achilles transection programme and from related connective-tissue models across multiple institutions.

Achilles transection — Krivic et al. (2006) [PMID:16609969]: Tomislav Krivic and colleagues in the Sikiric Zagreb group performed complete Achilles-tendon detachment in rats. BPC-157 (10 µg/kg, subcutaneous, near-site) was administered daily for 14 days post-surgery. At 2 and 4 weeks, treated animals showed significantly greater maximum load, stiffness, and energy to failure versus controls. Corticosteroid co-administration, which typically impairs tendon healing, was fully counteracted by BPC-157 in the same model — a finding with implications for research protocols involving anti-inflammatory co-treatment.

Tendon outgrowth and tenocyte migration — Chang et al. (2011) [PMID:21030672]: C.H. Chang's group used an ex vivo tendon-explant culture model alongside in vitro scratch-wound assays. BPC-157 significantly increased tendon outgrowth distance and velocity of tenocyte migration, with FAK and paxillin phosphorylation identified as the intracellular mediators. Critically, the effect was dose-dependent and observed at concentrations achievable with standard subcutaneous dosing, supporting translation of the rodent data.

Ligament healing — Cerovecki et al. (2010) [PMID:20225319]: Cerovecki and the Sikiric group examined BPC-157 in a rat medial collateral ligament (MCL) injury model. At 4 weeks, BPC-157-treated animals demonstrated superior collagen-fibre organisation and higher tensile strength versus controls, with histological evidence of reduced inflammatory infiltrate at the repair site. The MCL shares structural biology with the Achilles and provides a complementary model for assessing dense connective-tissue repair.

TB-500 tendon-adjacent data: Direct TB-500 tendon transection data is limited in the published record; the relevant tendon-fibroblast actin-remodelling evidence is extrapolated from Goldstein et al.'s (2005) [PMID:16099219] mechanistic framework and Crockford et al.'s (2010) [PMID:20536467] clinical-application review. Rotator-cuff and supraspinatus-repair models in the broader Tβ4 literature show consistent acceleration of fibroblast ingrowth and improved collagen organisation at 6 weeks. The combination with BPC-157 in tendon models specifically remains an area requiring direct study.

No human clinical-trial data exists for either compound in tendon repair. All findings cited above are from preclinical animal or in vitro research.

Full research protocol

The dosing below reflects the tendon-specific adaptation of the published animal-model parameters, with the BPC-157 local/systemic split as the defining modification.

Local vs systemic BPC-157 split: At each morning dose, BPC-157 is injected subcutaneously as close to the target tendon as safely accessible — typically the peri-Achilles subcutaneous tissue for Achilles-injury models, or the lateral shoulder for rotator-cuff models. The evening dose is standard systemic subcutaneous injection (abdomen or lateral thigh). This split is the defining methodological distinction versus the general healing stack and reflects the near-site delivery strategy validated in the Krivic et al. Achilles detachment model.

Weekly research timeline

• Loading phase (weeks 1–3): TB-500 at full 2.5 mg twice weekly; BPC-157 at 500 µg twice daily with local/systemic split. This 3-week loading window aligns with the acute angiogenic and tenocyte-migration phase documented in Chang et al.'s explant model.
• Consolidation phase (weeks 4–5): TB-500 reduces to once-weekly maintenance as tissue partitioning sustains the actin-remodelling signal. BPC-157 remains at full dose through week 4, then tapers in week 5.
• Taper (week 6): Both peptides at reduced maintenance doses. Avoids abrupt cessation, consistent with standard rodent-model protocol design.
• Post-cycle observation (weeks 7–10): TB-500's tissue-partitioning pharmacokinetics mean actin-remodelling and progenitor-cell signals persist for 10–14 days post-final-dose. Most published research protocols document a 4-week observation window before re-assessing structural endpoints.

Reconstitution & storage notes

Sterile preparation is particularly important for this protocol because the local peri-tendinous injection strategy introduces peptide into a relatively avascular, immunologically quiescent tissue compartment where any contamination carries an elevated risk of localised septic response in animal models.

Both peptides should be reconstituted with bacteriostatic water for injection (not standard sterile water, which lacks the bacteriostatic agent benzyl alcohol). BPC-157 reconstitutes readily at 1 mg/mL; the resulting solution is stable at 2–8 °C for approximately 30 days if kept in amber vials. TB-500 is less water-soluble and benefits from initial reconstitution with a small volume of bacteriostatic water followed by gentle rotation — do not vortex, as mechanical shear can degrade the actin-binding domain. TB-500 solutions at 2 mg/mL in bacteriostatic water are stable for approximately 21 days refrigerated.

For storage beyond 30 days, aliquot both solutions into single-use volumes before freezing at −20 °C. Repeated freeze-thaw cycles degrade both peptides measurably; label aliquots with date and thaw history. For local injection use, draw the local BPC-157 dose immediately before administration and do not pre-load syringes for peri-tendinous delivery.

Related research

The general BPC-157 + TB-500 healing stack covers the broader tissue-repair application of this peptide pair across GI, cardiovascular and soft-tissue models — the appropriate starting point if the research target is not tendon-specific. For more complex recovery models, the BPC-157 + TB-500 + GHK-Cu advanced recovery stack adds copper-peptide-driven matrix remodelling and antioxidant signalling to the base protocol. The Ipamorelin + CJC-1295 + BPC-157 recomp stack provides a growth-hormone-secretagogue context for BPC-157 when the research objective extends to body-composition modelling alongside connective-tissue repair.

For the full per-peptide monographs covering mechanism, safety profile and complete literature review, see PeptideAuthority.co.uk/peptides/bpc-157 and PeptideAuthority.co.uk/peptides/tb-500.